Can-Fite BioPharma Ltd.
Piclidenoson
Lowe Syndrome
Countdown
86days
Phase 2 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 2 trial results for Piclidenoson in Lowe Syndrome are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“Data Expected in Q3 2026”